NRAS mutant melanoma – undrugable?

NRAS mutant melanoma – undrugable?

Bibliographic Details
Main Authors:	Posch, Christian, Ortiz-Urda, Susana
Format:	Online
Language:	English
Published:	Impact Journals LLC 2013
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3720596/

Similar Items

Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma
by: Posch, C, et al.
Published: (2015)

MEK inhibitors for the treatment of NRAS mutant melanoma
by: Sarkisian S, et al.
Published: (2018-08-01)

Playing POLO-like kinase in NRAS mutant melanoma
by: Chen, Hsin-Yi, et al.
Published: (2015)

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer
by: Vujic, Igor, et al.
Published: (2014)

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells
by: Vujic, Igor, et al.
Published: (2016)

Variation of mutant allele frequency in NRAS Q61 mutated melanomas
by: Zofia Hélias-Rodzewicz, et al.
Published: (2017-07-01)

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma
by: Atefi, Mohammad, et al.
Published: (2015)

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
by: Wong, Deborah JL, et al.
Published: (2015)

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma
by: Wong, Deborah JL, et al.
Published: (2014)

Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin
by: Xia, Yun, et al.
Published: (2016)

MIG6 is MEK-regulated and affects EGF-induced migration in mutant NRAS melanoma
by: Vu, Ha Linh, et al.
Published: (2015)

α-Mangostin, a Natural Agent, Enhances the Response of NRAS Mutant Melanoma to Retinoic Acid
by: Xia, Yun, et al.
Published: (2016)

Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox
by: Goldenberg, Alina, et al.
Published: (2015)

Targeting the mTOR Complex by Everolimus in NRAS Mutant Neuroblastoma
by: Kiessling, Michael K., et al.
Published: (2016)

Spatial Reversal Learning in Chronically Sensitized Rats and in Undrugged Sensitized Rats with Dopamine D2-Like Receptor Agonist Quinpirole
by: Hatalova, Hana, et al.
Published: (2014)

NRAS and BRAF Mutations in Melanoma-Associated Nevi and Uninvolved Nevi
by: Tschandl, Philipp, et al.
Published: (2013)

Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma
by: Colombino, Maria, et al.
Published: (2013)

BRAF and NRAS Mutations are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma
by: Chiappetta, Caterina, et al.
Published: (2015)

BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib
by: Ranzani, Marco, et al.
Published: (2015)

Mutant NRASQ61 shares signaling similarities across various cancer types – potential implications for future therapies
by: Vujic, Igor, et al.
Published: (2014)

Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma
by: Birkeland, Einar, et al.
Published: (2013)

Deregulated Nras Expression in Knock-In Animals Harboring a Gammaretroviral Long Terminal Repeat at the Nras/Csde1 Locus
by: Ballarín-González, Borja, et al.
Published: (2013)

Correction: Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
by: Curl, Patti, et al.
Published: (2015)

Cost-Effectiveness of Treatment Strategies for BRAF-Mutated Metastatic Melanoma
by: Curl, Patti, et al.
Published: (2014)

Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients
by: Posch, C, et al.
Published: (2014)

Impact of NRAS Mutations on the Diagnosis of Follicular Neoplasm of the Thyroid
by: Bae, Ja-Seong, et al.
Published: (2014)

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases
by: Zebary, A, et al.
Published: (2013)

Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations
by: Shackelford, Rodney, et al.
Published: (2014)

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
by: Markus V. Heppt, et al.
Published: (2017-08-01)

NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand
by: Jones, Angela M., et al.
Published: (2016)

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
by: Mangana, Joanna, et al.
Published: (2015)

Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations
by: Chang-Hao Tsao, Simon, et al.
Published: (2015)

Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
by: Manca, Antonella, et al.
Published: (2015)

Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma
by: Carlino, M S, et al.
Published: (2014)

Dabrafenib for treatment of BRAF-mutant melanoma
by: Kainthla, Radhika, et al.
Published: (2013)

Optimizing the treatment of BRAF mutant melanoma
by: Settleman, Jeff
Published: (2014)

Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness
by: Li, Qing, et al.
Published: (2013)

Distribution of Agricultural NRAs across Countries and Products, 1955-84 and 1985-2007
by: Anderson, Kym, et al.
Published: (2017)

Prognostic Significance of NRAS Gene Mutations in Children with Acute Myelogenous Leukemia
by: Aly, Rabab M., et al.
Published: (2011)

Noonan syndrome gain-of-function mutations in NRAS cause zebrafish gastrulation defects
by: Runtuwene, Vincent, et al.
Published: (2011)